More than 900 US medical cannabis dispensaries have become the first operators in the country to hold federal registration, marking the first tangible change for operators since April’s partial rescheduling order.
Ascend Wellness Holdings (CSE: AAWH-U.CN / OTCQX: AAWH) has become the latest US multi-state cannabis operator to target an uplisting to a major exchange, following the landmark entrance of Trulieve (TRLV) onto the New York Stock Exchange (NYSE) last month.
Tomorrow (July 15, 2026) the landmark administrative hearing on US cannabis rescheduling will come to a close.
On Monday (June 29), the most consequential hearing in the history of US cannabis policy began proceedings, as the DEA and the seven invited representatives made their opening statements.
On June 29, 2026, one of the most consequential hearings in the history of US cannabis policy, the crucial DEA Administrative Law Judge (ALJ) hearing that could determine whether adult-use cannabis joins state-licensed medical cannabis on Schedule III of the Controlled Substances Act, begins proceedings.
In the weeks since cannabis under a state medical licence was moved to Schedule III, US multi-state operators (MSOs) have wasted no time in capitalising on the historic reclassification.
Trulieve’s uplisting to the NYSE, the first of its kind in US history, has undoubtedly caught the attention of every large North American cannabis operator.
The critical June 29 administrative hearing, set to determine whether the US will extend rescheduling efforts to recreational cannabis, is now set to be a fiercely contested event.
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to VER-01, the flagship full-spectrum cannabis drug from Munich-based Vertanical, putting it in prime position to become the first FDA-approved cannabis-derived medicine for pain, and only the second such approval since Epidiolex in 2018.
